^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HBM7004

    i
    Other names: HBM7004
    Associations

    News

    Trials
    Company:
    Harbour BioMed
    Drug class:
    CD3 agonist, B7-H4 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2years
    HBM7008 (B7H4x4-1BB HBICE) Synergizes HBM7004 (B7H4xCD3 HBICE) for Solid Tumor Therapy (SITC 2022)
    Ethics Approval The cancer tissue microarray was purchased from Fanpu Biotech, Inc. The company ensured ethical approval from the patients, and patient consent for publication.
    IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    HBM7004 • HBM7008